Iodixanol in Cardioangiography

1994 ◽  
Vol 35 (6) ◽  
pp. 614-618 ◽  
Author(s):  
K. Tveit ◽  
K.-D. Bolz ◽  
B. Bolstad ◽  
T. Haugland ◽  
K. J. Berg ◽  
...  
Keyword(s):  
Heart Rate ◽  
Renal Function ◽  
Adverse Events ◽  
Contrast Media ◽  
Contrast Medium ◽  
Normal Renal Function ◽  
Clinical Chemistry ◽  
Vital Signs ◽  
Diagnostic Information

Iodixanol (Visipaque) 320 mg I/ml, a non-ionic, dimeric, isotonic contrast medium, was compared to ioxaglate (Hexabrix) 320 mg I/ml in cardioangiography. One hundred and two patients with normal renal function were included in the study. The objectives were to evaluate safety, tolerability, radiographic efficacy and effects on renal function. Adverse events, discomfort, vital signs, clinical chemistry parameters, diagnostic information and radiographic density were recorded. Both contrast media had minor effects on the renal function parameters monitored. The patients who received iodixanol experienced fewer adverse events, significantly less discomfort and had a lower increase in heart rate than did the patients in the ioxaglate group. The radiographic efficacy was good in both groups. Iodixanol 320 mg I/ml is safe and effective for use in cardioangiography.

scholarly journals An Analysis of Exertional Safety After Blood Donation in Active Duty Military Personnel—A Feasibility Study

2020 ◽  
Author(s):  
Brandon M Carius ◽  
Mohamad Umar ◽  
James K Aden ◽  
Steve G Schauer
Keyword(s):  
Heart Rate ◽  
Adverse Events ◽  
Feasibility Study ◽  
Blood Donation ◽  
Vital Signs ◽  
Physical Fitness Test ◽  
Resuscitation Fluid ◽  
Baseline Testing ◽  
Military Populations ◽  
Armed Services

ABSTRACT Introduction Whole blood (WB) is the optimal resuscitation fluid in hemorrhagic shock. Military research focuses on mortality benefits of WB acquired through walking blood banks (WBBs). Few military-based studies on donation effects exist, almost exclusively performed on small special operation forces. No Department of Defense regulations for postdonation precautions in nonaviation crew members exist. Further study is warranted regarding safety and limitations in postdonation populations. Materials and Methods A feasibility (n = 25) prospective interventional study examined the safety of exertion (defined as a 1.6-km treadmill run at volunteers’ minimum passing pace for the Army Physical Fitness Test) following 1 unit of WB donation. Subjects served as their own controls, performing baseline testing 7 days before donation, with repeat testing 1 h following donation conducted by Armed Services Blood Program personnel. Adverse events, pre- and postexertion vital signs (VS) were evaluated. Results There were no adverse events throughout testing. Only resting heart rate (68 vs. 73 beats · min−1, p < 0.01) and postexertion heart rate were significantly different among pre- and postdonation VS. Additional significant findings were time to attain postexertion normocardia (116 vs. 147 seconds, p < 0.01). A small but statistically significant change in Borg perceived exertional scores was noted (10.3 vs. 10.8, p < 0.05). Conclusions This feasibility study demonstrates the first safety test of regular military populations performing exertion immediately following the standardized WB donation. VS changes may translate into a small but significant increase in perceived postdonation exertion. Future studies should expand duration and intensity of exertion to match combat conditions.

scholarly journals Active management of atrial fibrillation or flutter in emergency department patients with renal impairment is associated with a higher risk of adverse events and treatment failure

CJEM ◽  
2019 ◽  
Vol 21 (3) ◽  
pp. 352-360
Author(s):  
Frank X. Scheuermeyer ◽  
Hubert Wong ◽  
Tyler W. Barrett ◽  
Jim Christenson ◽  
Eric Grafstein ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Emergency Department ◽  
Renal Function ◽  
Adverse Events ◽  
Renal Impairment ◽  
Treatment Failure ◽  
Normal Renal Function ◽  
Odds Ratio ◽  
Adjusted Odds Ratio ◽  
Active Management

ABSTRACTObjectiveAtrial fibrillation or flutter (AFF) patients with renal impairment have poor long-term prognosis, but their emergency department (ED) management has not been described. We investigated the association of renal impairment upon outcomes after rate or rhythm control (RRC) including ED-based adverse events (AE) and treatment failure.MethodsThis cohort study used an electrocardiogram database from two urban centres to identify consecutive AFF patients and reviewed charts to obtain comorbidities, ED management, including RRC, prespecified AE, and treatment failure. Patients were dichotomized into a normal estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m2) or impaired renal function (“low eGFR”). Primary and secondary outcomes were prespecified AEs and treatment failure, respectively. We calculated 1) adjusted excess AE risk for patients with decreased renal function receiving RRC; and 2) adjusted odds ratio of RRC treatment failure.ResultsOf 1,112 consecutive ED AFF patients, 412 (37.0%) had a low eGFR. Crude AE rates for RRC were 27/238 (11.3%) for patients with normal renal function and 26/103 (25.2%) for patients with low eGFR. For patients with low eGFR receiving RRC, adjusted excess AE risk was 13.7%. (95% CI 1.7 to 25.1%). For patients with low eGFR, adjusted odds ratio for RRC failure was 3.07. (95% CI 1.74 to 5.43)ConclusionsIn this cohort of ED AFF patients receiving RRC, those with low eGFR had significantly increased adjusted excess risk of AE compared with patients with normal renal function. Odds of treatment failure were also significantly increased.

scholarly journals Changes in Biochemical, Strength, Flexibility, and Aerobic Capacity Parameters after a 1700 km Ultraendurance Cycling Race

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Vicente Javier Clemente-Suarez
Keyword(s):  
Heart Rate ◽  
Renal Function ◽  
Oxygen Uptake ◽  
Aerobic Capacity ◽  
Normal Renal Function ◽  
Ventilatory Threshold ◽  
Countermovement Jump ◽  
Training Interventions ◽  
Leg Strength ◽  
Recovery Times

The purpose of the present research was to study the organic response after ultraendurance cycling race. Selected biochemical, leg strength, flexibility, and aerobic capacity parameters were analyzed in 6 subjects 5 days before and 5 days after completing a 1700 km ultraendurance cycling race. After the race, participants presented a significant decrease in Hb (167.8 ± 9.5 versus 141.6 ± 15.7 mg/dL), strength (29.4 ± 2.7 versus 25.5 ± 3.7 cm in a countermovement jump), and oxygen uptake and heart rate at ventilatory threshold (1957.0 ± 458.4 versus 1755.2 ± 281.5 mL/kg/min and 140.0 ± 9.7 versus 130.8 ± 8.3 bpm, resp.). Testosterone presented a decrease tendency (4.2 ± 2.5 versus 3.9 ± 2.6 ng/L) in opposition to the increase tendency of cortisol and ammonium parameters. Transferrin and iron levels presented high values related to an overstimulation of the liver, a normal renal function, a tendency to decrease flexibility, and an increase in aerobic capacity, finding a tendency to increase the absolute maximal oxygen uptake (37.2 ±2.4 versus 38.7 ± 1.8 mL/min) in contrast to previous studies conducted with subjects with similar age. These results can be used to program training interventions, recovery times between probes, and nutritional and/or ergonomic strategies in ultraendurance events.

Urinary Protein Excretion following Intravenously Administered Ionic and Non-Ionic Contrast Media in Man

1989 ◽  
Vol 30 (5) ◽  
pp. 517-519 ◽  
Author(s):  
N. Skovgaard ◽  
J. Holm ◽  
L. Hemmingsen ◽  
P. Skaarup
Keyword(s):  
Renal Function ◽  
Contrast Media ◽  
Urinary Excretion ◽  
Normal Renal Function ◽  
Binding Protein ◽  
Protein A ◽  
Urinary Protein Excretion ◽  
Urinary Protein ◽  
Protein Excretion ◽  
Proximal Tubular

Urinary protein excretion following intravenous administration of the radiographic contrast media (CM) diatrizoate (ionic) and iopromide (non-ionic) was examined in 20 patients with normal renal function. Neither of the two CM had any effect on the 24-h urinary excretion of albumin (a marker of glomerular proteinuria). The 24-h urinary excretion of the retinol-binding protein (a marker of low molecular weight or tubular proteinuria) and the folate binding protein, a protein localized in the brush-border membranes of the proximal tubular cells, showed a statistically significant transient increase the day after diatrizoate injection, whereas no increase was observed after iopromide. Thus, only a minimal and temporary disturbance of the renal proximal tubular function was observed after diatrizoate injection in patients with normal renal function.

HEART RATE IS ASSOCIATED WITH RENAL PARAMETERS IN PATIENTS WITH TYPE 1 DIABETES AND NORMAL RENAL FUNCTION

2018 ◽  
Vol 36 (Supplement 1) ◽  
pp. e190-e191
Author(s):  
T. Bulum ◽  
I. Prkacin ◽  
V. Roso ◽  
L. Duvnjak
Keyword(s):  
Heart Rate ◽  
Type 1 Diabetes ◽  
Renal Function ◽  
Normal Renal Function

Low Dose Urography

1986 ◽  
Vol 27 (5) ◽  
pp. 557-559 ◽  
Author(s):  
L. Björk ◽  
B. F. Zachrisson
Keyword(s):  
Renal Function ◽  
Body Weight ◽  
Adverse Effects ◽  
Contrast Media ◽  
Normal Renal Function ◽  
Low Dose

Three modern low osmolar contrast media (Iopamiro, Omnipaque and Hexabrix) were injected intravenously in 150 patients. They were all effective for urography in a concentration iso-osmolar to blood and with a dose of 90 mg I/kg body weight in patients with normal renal function. In patients with decreased renal function, this low dose is not sufficient and should be doubled. No significant diagnostic differences between the three media were found. The subjective and objective adverse effects were minimal and transient.

Interaction between Beta-Blockers and Contrast Media during Intracoronary Administration in Rabbit Heart

1994 ◽  
Vol 35 (1) ◽  
pp. 70-76
Author(s):  
K. Salbaş ◽  
G. Akgün ◽  
G. Pamīr ◽  
T. Gürel
Keyword(s):  
Heart Rate ◽  
Contrast Media ◽  
Contrast Medium ◽  
Beta Blocker ◽  
Beta Blockers ◽  
Rabbit Heart ◽  
Force Of Contraction ◽  
Contraction Rate ◽  
Resting Tension ◽  
Pr Interval

The effects of ionic, meglumine sodium diatrizoate (Urografin 76) and nonionic, iohexol contrast media were examined in the absence and presence of propranolol, a beta-blocker having nonspecific membrane stabilizing action and atenolol, a beta-blocker lacking nonspecific membrane stabilizing action on Langendorff-perfused rabbit hearts. Contrast medium, 0.7 ml, was injected into the aortic root in the absence and presence of 10−7 and 10−5 M beta-blocker to observe the changes in resting tension, force of contraction, rate of contraction, heart rate and PR interval. Beta-blockers and contrast media interact in affecting myocardial contractility, heart rate and atrioventricular conduction. The interaction is milder when the beta-blocker lacks membrane stabilizing activity and the contrast medium is nonionic.

Iodixanol — A New Nonionic Dimer — In Aortofemoral Angiography

1992 ◽  
Vol 33 (6) ◽  
pp. 611-613 ◽  
Author(s):  
U. Albrechtsson ◽  
H. Lárusdóttir ◽  
L. Norgren ◽  
B. Lundby
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Contrast Medium ◽  
Short Duration ◽  
Clinical Importance ◽  
Diagnostic Information ◽  
The Other ◽  
Serum Chemistry ◽  
Significant Difference

In 26 patients iodixanol, a new nonionic dimer, isotonic to blood in all concentrations, was used as contrast medium in aortofemoral angiography. Half of the patients received contrast medium in a concentration of 270 mg I/ml and the other half 320 mg I/ml. The aim of the trial was to evaluate the safety and tolerability of iodixanol and the radiographic efficacy of the two concentrations. The degree of discomfort, adverse events, changes in serum chemistry parameters, and diagnostic information were assessed. There were no changes or trends of clinical importance in serum chemistry parameters. The side effects were mild and consisted mostly of some sensation of warmth of short duration. No other adverse events were seen. The overall radiographic efficacy did not show any significant difference between the two concentrations. This indicates that iodixanol is safe and well tolerated when used in adult femoral angiography.

scholarly journals Tolerability of Capsaicinoids fromCapsicumExtract in a Beadlet Form: A Pilot Study

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Jayant Deshpande ◽  
Shankaranarayanan Jeyakodi ◽  
Vijaya Juturu
Keyword(s):  
Adverse Events ◽  
Skin Color ◽  
Complete Blood Count ◽  
Clinical Chemistry ◽  
Vital Signs ◽  
Dose Finding ◽  
Hair Color ◽  
Open Label ◽  
Serious Adverse Events ◽  
Function Tests

A single center, open-label, dose-finding adaptive study was conducted in twelve healthy overweight female subjects. The study was to evaluate the safety and tolerability of the capsaicinoids (CAPs) fromCapsicumextract in a beadlet form compared to placebo in a healthy overweight population. The investigational product capsaicinoids (CAPs) fromCapsicumextract in a beadlet form (Capsimax®) a proprietary encapsulated form ofCapsicumextract in beadlet form supplemented at 2 mg, 4 mg, 6 mg, 8 mg and 10 mg of CAPs. An ascending dose protocol evaluated a total dose of 10 mg daily given in five divided doses (2 mg, 4 mg, 6 mg, 8 mg and 10 mg of CAPs). Each dose was given for a week. Safety and tolerability were assessed. Primary outcomes were tolerability assessments and reports of adverse events. Tolerability assessments were observed on skin color and any changes in skin, bowel movement, digestion, mouth or throat, hair color or changes in hair color, urination includes frequency and burning sensations, breathing, any changes in their health. Secondary outcomes were body weight, body mass index (BMI), blood pressure (SBP/DBP), vital signs, electrocardiograms, clinical chemistry parameters including liver function tests, lung function tests and kidney function tests and complete blood count (CBC). No dose effective changes were observed. The escalating dose levels of CAPs in a beadlet form product found was tolerable and safe for weight management studies. Tolerability assessments and safety blood markers showed no significant changes from baseline. No significant serious adverse events were reported throughout the duration of the study. Further longer term studies are required to explore the tolerability of the product. This trial is registered with ISRCTN: #  ISRCTN10975080.

Sign in / Sign up

Export Citation Format

Share Document